Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» wet age-related macular degeneration
wet age-related macular degeneration
Early snapshot of Adverum's eye gene therapy sparks concern about vision loss
Endpoints
Sat, 09/14/19 - 11:25 am
Adverum Biotechnologies
wet age-related macular degeneration
gene therapy
ADVM-022
3 Drugs Under FDA Review With Blockbuster Potential
Motley Fool
Fri, 06/21/19 - 11:24 am
AbbVie
Upadacitinib
rheumatoid arthritis
Novartis
brolucizumab
wet age-related macular degeneration
Celgene
ozanimod
relapsing multiple sclerosis
Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study
Yahoo/Zacks.com
Tue, 05/21/19 - 09:35 am
Adverum Biotechnologies
FDA
clinical trials
ADVM-022
wet age-related macular degeneration
FDA accepts BLA for Novartis' AMD therapy
BioCentury
Mon, 04/15/19 - 11:31 pm
Novartis
FDA
wet age-related macular degeneration
brolucizumab
Adverum Bio offers a late notification about FDA hold on lead gene therapy for wet AMD
Endpoints
Mon, 04/15/19 - 11:12 pm
Adverum Biotechnologies
CMC
gene therapy
wet age-related macular degeneration
FDA
Allergan eye drug fails to impress on safety, upping pressure ahead of key meeting
Biopharma Dive
Wed, 04/3/19 - 12:22 pm
Allergan
abicipar
wet age-related macular degeneration
Does an improved safety profile strengthen Allergan's case for a wet AMD challenge to Lucentis?
Endpoints
Tue, 04/2/19 - 12:04 pm
Allergan
abicipar
wet age-related macular degeneration
Lucentis
Molecular Partners
Outlook Therapeutics Files for $57 Million Offering
CP Wire
Thu, 02/21/19 - 11:58 am
Outlook Therapeutics
wet age-related macular degeneration
Ocular Therapeutix doses first wet-AMD patient in implant trial
Drug Delivery Business News
Wed, 02/20/19 - 06:11 pm
Ocular Therapeutix
wet age-related macular degeneration
devices
OTX-TKI
Ophthotech Completes Recruitment for Ph IIb Trial of Zimura for Geographic Atrophy Secondary to Dry AMD
CP Wire
Thu, 10/4/18 - 09:36 am
Opthotech
Zimura
wet age-related macular degeneration
dry age-related macular degeneration
Stargardt disease
Ophthotech Completes Recruitment for Ph IIb Trial of Zimura for Geographic Atrophy Secondary to Dry AMD
Thu, 10/4/18 - 12:45 pm
Opthotech
Zimura
wet age-related macular degeneration
dry age-related macular degeneration
Stargardt disease
[video+transcript]Gene Therapy Could Be a Boon for This Biotech
Motley Fool
Sun, 09/30/18 - 03:38 pm
gene therapy
Rengexbio
spinal muscular atrophy
wet age-related macular degeneration
Novartis, Bayer consider appeal as court says Avastin can be used in AMD
Pharmaforum
Mon, 09/24/18 - 03:37 pm
UK
Roche
Avastin
wet age-related macular degeneration
Novartis
Bayer
Just a few days after a stumble, FDA OKs 12-week dose for Eylea as Regeneron braces for Novartis attack
Endpoints
Fri, 08/17/18 - 09:28 am
FDA
Eylea
Regeneron
Novartis
wet age-related macular degeneration
Racing Novartis on Eylea rival, the FDA trips up Regeneron at the finish line
Endpoints
Mon, 08/13/18 - 11:39 am
Regeneron
Eylea
Novartis
RTH258
wet age-related macular degeneration
FDA
Allergan’s eye contender cannot knock Eylea off its perch
EP Vantage
Sun, 07/22/18 - 12:24 pm
Regeneron
Eylea
wet age-related macular degeneration
Allergan
molecular
abicipar
Adverum Biotechnologies Announces Positive Results in Preclinical Study of ADVM-022 Gene Therapy in Wet AMD
CP Wire
Tue, 05/1/18 - 11:15 am
Adverum Biotechnologies
ADVM-022
wet age-related macular degeneration
Adverum Biotechnologies Announces Positive Results in Preclinical Study of ADVM-022 Gene Therapy in Wet AMD
Tue, 05/1/18 - 09:42 am
Adverum Biotechnologies
macular degeneration
wet age-related macular degeneration
Eyeing Eylea’s $5B sales, Novartis touts solid 12-week dosing data for its rival RTH258
Endpoints
Mon, 04/30/18 - 09:04 pm
Novartis
Regeneron
Eylea
RTH258
wet age-related macular degeneration
Mylan, Momenta take aim at Regeneron’s Eylea with biosimilar
Drug Delivery Business News
Thu, 01/4/18 - 11:01 am
Mylan Labs
Momenta Pharmaceuticals
Regeneron
Eylea
biosimilars
diabetic macular edema
wet age-related macular degeneration
M710
Pages
« first
‹ previous
1
2
3
4
5
next ›
last »